Switching Antipsychotics Reduces Cardiovascular Risk Factors Carlat Reports

Switching Antipsychotics Reduces Cardiovascular Risk Factors

The Carlat Psychiatry Report, Volume 9, Number 11, November 2011
https://www.thecarlatreport.com/newsletter-issue/tcprv9n11/

From The Carlat Psychiatry Report, November 2011, Insomnia

Issue Links: Learning Objectives | Editorial Information

Topics: Antipsychotics

Glen Spielmans, PhD

If patients are stable on olanzapine (Zyprexa), quetiapine (Seroquel), or risperidone (Risperdal) but are experiencing adverse metabolic effects, it might make sense to switch to a medication that has a lower risk of causing such effects. But would such a switch reduce obesity and cholesterol at the risk of a relapse?

You can't view details of this content, please login or buy subscription here

Glen Spielmans, PhD

Associate professor of psychology, Metropolitan State University, St. Paul, MN

Glen Spielmans, PhD, has disclosed that he has no relevant financial or other interests in any commercial companies ertaining to this educational activity.